Asia Pacific
Refine Search
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Biotechnology
Japanese drugmaker Otsuka Pharmaceutical has announced positive preliminary results from two, Phase II/III trials for fremanezumab as a prophylactic migraine drug. 28 January 2020
Pharmaceutical
As the general public and drugmakers alike scramble to find out more information about the emerging coronavirus outbreak in Wuhan, China, the US regulator has provided an update on critical actions to advance medical countermeasures. 28 January 2020
Biotechnology
The Japanese health authorities have approved Cimzia (certolizumab pegol) to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. 28 January 2020
Biotechnology
Japan Tobacco and Torii Pharmaceutical have received manufacturing and marketing approval for Corectim Ointment 0.5% (delgocitinib; formerly JTE-052), a Janus kinase (JAK) inhibitor, for an indication of atopic dermatitis in Japan. 27 January 2020
Pharmaceutical
Propess (dinoprostone) has been approved by the Minister of Health, Labour and Welfare in Japan for initiation of cervical ripening in patients at term. 23 January 2020
Biotechnology
Japanese drugmaker Astellas Pharma has sold the stake in its joint venture (JV) with US biotech major Amgen. 23 January 2020
Pharmaceutical
Eisai clocked up Japanese approvals for two of its drugs on Thursday. 23 January 2020
Pharmaceutical
In November 2019, China updated its National Reimbursement Drug List (NRDL) to include 70 new medicines, with an average price cut of 61% agreed by pharma companies. 23 January 2020
Biotechnology
Asian-Pacific contract research organization (CRO) Novotech has issued a report describing a record year for clinical trials, as defined by numbers of studies, investigators, and patient enrollment. 22 January 2020
Generics
The second round of China’s national generics procurement, which ended on January 17, saw 53% price cuts on average of the 32 drugs that treat diseases including cancer and type II diabetes. 22 January 2020
Biotechnology
Chinese biotech start-up Antengene recently hired two former high-profile managers from its funding partner Celgene, now a Bristol-Myers Squibb (NYSE: BMY) company. In a recent meeting in Shanghai, where Antengene is based, founder and chief executive Jay Mei spoke with The Pharma Letter about the hires and his vision for his company. 16 January 2020
Pharmaceutical
ViiV Healthcare says it has obtained approval of Dovato (dolutegravir 50mg/lamivudine 300mg) from the Japan Ministry of Health, Labor and Welfare. 15 January 2020
Pharmaceutical
UK-based Shield Therapeutics has entered into an exclusive licence agreement for its lead product Feraccru/Accrufer (ferric maltol) with Beijing Aosaikang Pharmaceutical (ASK Pharm) in China, Hong Kong, Macau and Taiwan. 13 January 2020
Biotechnology
Danish allergy immunotherapy specialists ALK-Abelló has initiated a new Phase III trial in China for its house dust mite (HDM) allergy program. 13 January 2020
Pharmaceutical
Japanese pharma major Eisai saw its shares gain 1.6% to 8,267 yen today as it announced the launch of in-house developed anticancer agent Halaven (eribulin mesylate) in China. 10 January 2020
Biotechnology
Ambitious dermatology specialist Almirall has announced a deal with China-based WuXi Biologics. 9 January 2020
Pharmaceutical
China's National Medical Products Administration (NMPA) has recently approved Shanghai Green Valley Pharmaceuticals’ brown algae-extracted drug – oligomannate (GV-971) – for mild to moderate Alzheimer's disease. 9 January 2020
Biotechnology
Japanese drugmaker Kyowa Kirin today said that it has submitted a supplemental application for Lumicef (brodalumab) for the treatment of axial spondyloarthritis (axSpA) in Japan. 8 January 2020
Pharmaceutical
Among regulatory news of note, China’s BeiGene gained its first drug approval on its domestic market, that of tislelizumab for Hodgkin’s lymphoma. M&A events saw Swiss pharma giant Roche finally gain clearance from competition authorities to close its $4.3 billion acquisition of gene therapy developed Spark Therapeutics. On the research front, Axsome Therapeutics last week released positive results for its migraine drug candidate AXS-07. It also has an interesting depression drug candidate in development. But there was disappointment for Incyte with the failure of its Phase III itacitinib trial in graft versus host disease. 5 January 2020
Generics
STA Pharmaceuticals (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China. 3 January 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze